Prevalence of Triple Negative Breast Cancers from a Hospital-Based Cancer Registry in a Tertiary Care Hospital in Kerala, South India
World Journal of Public Health
Volume 4, Issue 2, June 2019, Pages: 43-46
Received: Jun. 16, 2019;
Accepted: Jul. 3, 2019;
Published: Jul. 16, 2019
Views 269 Downloads 50
Neena Mary, Amala Institute of Medical Sciences, Thrissur, South India
Catherin Nisha, Department of Community Medicine, Amala Institute of Medical Sciences, Thrissur, India
Kerline Jerome, Department of Community Medicine, Amala Institute of Medical Sciences, Thrissur, India
Clint Vaz, Department of Community Medicine, Amala Institute of Medical Sciences, Thrissur, India
Vijayalaxmi Nair, Department of Pathology, Amala Institute of Medical Sciences, Thrissur, India
Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and over expression of Human epidermal growth factor receptor 2 (Her2neu). They are typically high-grade tumors and occur in young females. Our study is to determine the prevalence of triple negative breast cancers from a hospital-based cancer registry in the year 2016. This is a retrospective, descriptive study where secondary data analysis was done, by obtaining data from the hospital-based immunohistochemistry (IHC) register. The Estrogen receptor, Progesterone receptor and Her2neu receptor status of the breast cancers which presented to the hospital and the referral cases received for IHC in the year 2016 was obtained from the register which totaled to 335 cases. The type of breast carcinoma was also noted. In our study the mean age of breast cancer patients was 56.2±12.387 years. There was 331 (98.8%) females among the study population. The most prevalent type of breast cancer was invasive ductal carcinoma which was 330 (98.5%). We also found out the prevalence of mono negative, bi negative and triple negative breast cancers. The prevalence of triple negative breast cancer was 58 (17.31%). There was no statistically significant difference found between prevalence of triple negative breast cancer and age. Our study showed that the prevalence of triple negative receptor breast was 17.31% among the study population. This study would serve as a baseline study for further research to open up new therapeutic possibilities.
Prevalence of Triple Negative Breast Cancers from a Hospital-Based Cancer Registry in a Tertiary Care Hospital in Kerala, South India, World Journal of Public Health.
Vol. 4, No. 2,
2019, pp. 43-46.
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Babita SK, Krishnadas V, Saju C, Vidhu J, Catherin N. Prevalence of cancers from a hospital based cancer registry in a tertiary care hospital in South India. Inter J of Scient Resear and Edu 2015; 3: 4638-40.
Babu GR, Lakshmi SB, Thiyagarajan JA. Epidemiological Correlates of Breast Cancer in South India. Asian pacific jour of cancer prevent 2013; 14: 5077-83.
Ferlay JHC, Autier P, Sankaranarayanan R. Global Burden of Breast Cancer. Breast Can Epid 2010; 6: 1-19.
Available from: https://en.m.wikipedia.org/wiki/Breast_ cancer_classification. Last accessed on December 2018.
Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer latest research and clinical prospects. Therap advan in medical oncol2013; 5: 169-81.
Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience. Nat Reviews Clini Oncol 2010; 7: 683-92.
William D, Foulkes WD, Smith IE, Jorge S, Reis-Filho. Triple-Negative Breast Cancer, The new Engl J of Medicin 2010; 363: 1938-48.
Available from https://www.medicinenet.com/script/main/art.asp?articlekey=11697 last accessed on March 2019.
Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. Asian pacific J of Can Prevent 2011; 12: 625-29.
Khabaz MN. Immunohistochemistry Subtypes (ER/PR/HER) of Breast Cancer: Where Do We Stand in the West of Saudi Arabia? Asian pacific J of Can Prevention 2014; 15: 8395-400.
Stead LA, Lash TL, Sobieraj JE, Chi DD, Westrup JL, Charlot M et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Canc Resear 2009; 11: 18.
Ghosh S, Sarkar S, Simhareddy S, Kotne S, Rao PBA, Turlapati SPV. Clinico-Morphological Profile and Receptor Status in Breast Cancer Patients in a South Indian Institution. Asian pacific J of Can Prevention 2014; 15: 7839-42.
Ian SF, Alain F, Gabriel N, Hortobagyi. Male breast cancer. The Lancet 2006; 367: 595-604.
Rao C, Shetty J, Kishan HL. Morphological profile and receptor status in breast carcinoma: An institutional study. Jour of Can Resear and Therap 2013; 9: 44-9.
Sughayer MA, Al-Khawaja MM, Massarweh S. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Path Onco Resear 2006; 12: 83-6.
Runnak MA, Hazha MA, Hemin HA, Abdulmahdi WA, Rashid MR, Hughson MD. A population.
Bsed study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data. BMC Womens Health 2012; 12: 16-25.
Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Can Resear and Treat 2011; 126: 185-92.
Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7: 134.
Li CY, Sheng ZS, Zhang XB, Wang P, Hou GF, Zhan J. Clinicopathological and Prognostic Characteristics of Triple Negative Breast Cancer (TNBC) in Chinese Patients: A Retrospective Study. Asian Paci Organiz for Can Preven 2013; 14: 3779-84.